Zhou Li, Wu Shaoqun, Wang Yong, Bao Xianyi, Peng Tingting, Luo Wenjing, Ortega-Usobiaga Julio
Aier Eye Hospital of Wuhan University (Wuhan Aier Eye Hosptial), Wuhan, China.
Department of Cataract and Refractive Surgery, Clínica Baviera, Aier Eye Hospital, Bilbao, Spain.
Front Med (Lausanne). 2022 Dec 16;9:1078237. doi: 10.3389/fmed.2022.1078237. eCollection 2022.
This study aimed to investigate the clinical presentation of acute primary angle closure (APAC) during the COVID-19 epidemic lockdown in Wuhan.
Consecutive patients seeking APAC treatment at the Wuhan Aier Eye Hospital during the 76 days (January 23-April 8, 2020) when the lockdown policy was implemented due to the COVID-19 pandemic were compared to those during the same period the following year (January 23-April 8, 2021), when the lockdown policy was not implemented. The cohorts were compared to assess demographic variables and clinical presentations.
A total of 54 patients (64 eyes) were included in the 2020, compared with 46 patients (51 eyes) in the 2021. Demographic factors were similar between the groups. Significantly more patients developed blindness in the 2020 cohort (21.87%) than in the 2021 cohort (7.84%). Patients in the 2020 showed a longer time from symptom to treatment (241.84 ± 211.95 h in 2020 vs. 121.53 ± 96.12 h in 2021; = 0.001), higher intraocular pressure at presentation (52.63 ± 12.45 mmHg in 2020 vs. 45.16 ± 9.79 mmHg in 2021; = 0.001), larger pupil diameter (5.47 ± 1.62 mm in 2020 vs. 4.33 ± 1.27 mm in 2021; = 0.001), and more glaucomatous optic neuropathy diagnoses [20/64 eyes (31.25%) in 2020 vs. 7/51 eyes (13.73%) in 2021; = 0.03].
The time between the onset of APAC symptoms and its treatment during the COVID-19 epidemic lockdown was significantly prolonged, which increased the blindness rate of APAC patients.
本研究旨在调查武汉新冠疫情封锁期间急性原发性闭角型青光眼(APAC)的临床表现。
将2020年因新冠疫情实施封锁政策的76天内(2020年1月23日至4月8日)在武汉爱尔眼科医院寻求APAC治疗的连续患者与次年同期(2021年1月23日至4月8日,未实施封锁政策)的患者进行比较。对两组队列进行比较以评估人口统计学变量和临床表现。
2020年共纳入54例患者(64只眼),2021年为46例患者(51只眼)。两组间人口统计学因素相似。2020年队列中失明的患者(21.87%)明显多于2021年队列(7.84%)。2020年的患者从症状出现到治疗的时间更长(2020年为241.84±211.95小时,2021年为121.53±96.12小时;P = 0.001),就诊时眼压更高(2020年为52.63±12.45 mmHg,2021年为45.16±9.79 mmHg;P = 0.001),瞳孔直径更大(2020年为5.47±1.62 mm,2021年为4.33±1.27 mm;P = 0.001),青光眼性视神经病变诊断更多[2020年为20/64只眼(31.25%),2021年为7/51只眼(13.73%);P = 0.03]。
新冠疫情封锁期间APAC症状出现至治疗的时间显著延长,这增加了APAC患者的失明率。